Essential Pharma和Clinigen扩大合作，改善JAPAC患者的可及性-动脉网

Essential Pharma and Clinigen Expand Collaboration to Improve Patient Access in JAPAC

PHARMA FOCUS ASIA 等信源发布 2025-02-07 13:56



可切换为仅中文







Essential Pharma an international specialty pharma group focused on ensuring that patients have access to low volume, clinically differentiated, niche pharmaceutical products across key therapeutic areas, and Clinigen, the global specialty pharmaceutical services group, today announced an expansion of their JAPAC collaboration, aimed at driving continued patient access to four therapies in Japan and Korea, and strengthening their combined market presence in the region..

Essential Pharma是一家国际专业制药集团，专注于确保患者在关键治疗领域获得低容量，临床差异化，利基制药产品，全球专业制药服务集团Clinigen今天宣布扩大其与日本的合作，旨在推动患者在日本和韩国继续获得四种疗法，并加强其在该地区的综合市场占有率。。

This expanded collaboration encompasses several new market authorisation transfer and exclusive distribution agreements. Building on their 2024 agreement for IOPIDINE® (apraclonidine) in Korea, Essential Pharma and Clinigen now extend this to Japan. New agreements establish market authorisation transfer and exclusive distribution for HALDOL® (haloperidol) and REMINYL® (galantamine) oral capsules in Korea, and for HALOMONTH® (haloperidol decanoate) in Japan..

这种扩大的合作包括几个新的市场授权转让和独家经销协议。Essential Pharma和Clinigen在2024年与韩国签订的IOPIDINE®（apraclonidine）协议的基础上，现在将其扩展到日本。新协议确立了韩国HALDOL®（氟哌啶醇）和REMINYL®（加兰他敏）口服胶囊以及日本Halomount®（氟哌啶醇癸酸酯）的市场授权转让和独家经销。。

IOPIDINE 5mg/ml is a short-term adjunctive therapy for patients with chronic glaucoma on maximally tolerated medical therapy to prevent or control intraocular pressure.

碘哌啶5mg/ml是慢性青光眼患者的短期辅助治疗，用于最大限度耐受药物治疗以预防或控制眼压。

HALDOL and HALOMONTH are antipsychotic drugs that contain haloperidol and are used in the treatment of schizophrenia and other psychiatric conditions including schizoaffective disorder. Haloperidol is included in the 2023 World Health Organization’s List of Essential Medicines[1].

HALDOL和HALOMONTH是含有氟哌啶醇的抗精神病药物，用于治疗精神分裂症和其他精神疾病，包括分裂情感障碍。氟哌啶醇被列入2023年世界卫生组织基本药物清单（1）。

REMINYL, a cholinesterase inhibitor, is a central nervous system (CNS) drug used to treat symptomatic mild to moderately severe dementia of the Alzheimer type.

雷米尼是一种胆碱酯酶抑制剂，是一种中枢神经系统（CNS）药物，用于治疗阿尔茨海默病型症状性轻度至中度重度痴呆。

Essential Pharma CEO Emma Johnson and Clinigen CEO Jerome Charton held a ceremonial signing event yesterday. While initially focused on ensuring continuity of patient access in the JAPAC region, both organisations envision further strategic partnering, supporting Essential Pharma’s goal to build on its diversified portfolio and late-stage pipeline focused on central nervous system, gastroenterology, ophthalmology, and rare disease, and leveraging Clinigen’s rare disease and orphan drug expertise, to improve access to innovative medicines for patients globally..

Essential Pharma首席执行官艾玛·约翰逊（EmmaJohnson）和Clinigen首席执行官杰罗姆·沙顿（JeromeCharton）昨天举行了一场签约仪式。虽然最初专注于确保日本地区患者获得治疗的连续性，但这两个组织都设想进一步开展战略合作，支持Essential Pharma的目标，即建立其多元化的投资组合和专注于中枢神经系统、胃肠病学、眼科学和罕见病的晚期管道，并利用Clinigen的罕见病和孤儿药专业知识，以改善全球患者获得创新药物的机会。。

Emma Johnson, CEO of Essential Pharma, says:

Essential Pharma首席执行官艾玛·约翰逊（EmmaJohnson）表示：

“Essential Pharma is delighted to expand our relationship with Clinigen as we continue to execute our strategy to become a leading, global specialty pharma group with a growing rare disease presence. Clinigen’s expertise in providing access to established brands as well as their expertise in the rare disease and orphan drug space makes them the ideal partner as we broaden access to our therapies and reinforce our strategic foothold in JAPAC.

“Essential Pharma很高兴扩大与Clinigen的关系，因为我们将继续执行我们的战略，成为一家领先的全球专业制药集团，拥有越来越多的罕见病业务。Clinigen在为知名品牌提供服务方面的专业知识，以及他们在罕见病和孤儿药领域的专业知识，使他们成为我们扩大治疗渠道和巩固我们在日本的战略立足点的理想合作伙伴。

Guided by our shared patient-centric values, this collaboration represents a significant step forward in our commitment to serving patients in the JAPAC region and beyond.”.

在我们共同的以患者为中心的价值观的指导下，这一合作标志着我们在致力于为日本及其他地区的患者提供服务方面迈出了重要的一步。”。

Jerome Charton, CEO of Clinigen, says:

Clinigen首席执行官杰罗姆·沙顿（JeromeCharton）表示：

“Our biggest achievements are marked by expanding patient access to much-needed medicines. While we are seeing the expansion of life sciences, R&D and clinical trials, population health is also becoming increasingly complex, and it is pertinent that patients do not feel the impact. With our trusted and equally motivated partner, Essential Pharma, Clinigen will further our mission to accelerate access to innovative medicines for patients worldwide.”.

“我们最大的成就是扩大了患者获得急需药物的机会。虽然我们看到生命科学，研发和临床试验的扩大，但人口健康也变得越来越复杂，患者不会感受到影响是有意义的。与我们值得信赖且同样积极的合作伙伴Essential Pharma一起，Clinigen将进一步推动我们的使命，以加速全球患者获得创新药物。”。

About Essential Pharma

关于Essential Pharma

Essential Pharma is an international specialty pharmaceutical group dedicated to maintaining access to clinically differentiated, niche, branded medicines across multiple therapeutic areas. The group has been an important and valued partner to healthcare providers for over 20 years by giving underserved patient populations access to medicines that otherwise might not be available, and addressing clinical unmet needs.

Essential Pharma是一家国际专业制药集团，致力于在多个治疗领域保持临床差异化，利基化，品牌化药物的使用。20多年来，该集团一直是医疗保健提供者的重要和有价值的合作伙伴，为服务不足的患者提供可能无法获得的药物，并解决临床未满足的需求。

Essential Pharma operates globally in more than 70 countries, supplying a portfolio of products with a focus on the central nervous system (CNS), gastroenterology, ophthalmology, and rare disease. The group’s growth strategy is centred on portfolio optimisation and a targeted M&A approach to acquire commercial and late-clinical stage assets in the four therapeutic areas of focus.

Essential Pharma在全球70多个国家运营，提供一系列产品，重点关注中枢神经系统（CNS）、胃肠病学、眼科学和罕见病。该集团的增长战略集中于投资组合优化和有针对性的并购方法，以收购四个治疗重点领域的商业和晚期临床阶段资产。

It is a trusted partner to multiple pharma companies of all sizes, with a proven history of integrating assets and managing complex technology transfers seamlessly while ensuring continuous supply to patients..

它是多家规模不一的制药公司值得信赖的合作伙伴，在整合资产和无缝管理复杂技术转让的同时确保向患者持续供应方面有着悠久的历史。。

For more information, please visit essentialpharmagroup.com.

有关更多信息，请访问essentialpharmagroup.com。

About Clinigen

关于Clinigen

Clinigen is a global, specialist pharmaceutical services company focused on providing ethical access to medicines. Its mission is to accelerate access to medicines for patients in every corner of the globe. The Group supports pharmaceutical and biotech companies across the medical product lifecycle, from clinical through to commercial and operates from sites in North America, Europe, Africa, and the Asia Pacific.

Clinigen是一家全球性的专业制药服务公司，专注于提供符合道德规范的药品。它的使命是加速全球每个角落的患者获得药物。该集团在整个医疗产品生命周期（从临床到商业）为制药和生物技术公司提供支持，并在北美、欧洲、非洲和亚太地区运营。

Clinigen has more than 1,100 employees across five continents in 15 countries and provides access in more than 130 countries every year..

Clinigen在五大洲的15个国家拥有1100多名员工，每年在130多个国家提供访问服务。。

For more information, please visit www.clinigen.com.

有关更多信息，请访问www.clinigen.com。

Contacts

联系人

Essential Pharma

基本药物

Emma Johnson, CEO

首席执行官Emma Johnson

Tel: +44(0)1784 477 167